Physician profile
Anna George
NPI 1710991906
$17,133.34
in general payments reported to CMS, 2019-2025
42 companies · $4,279 in 2025
The $4,279 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,372 · 2020: $1,207 · 2021: $1,843 · 2022: $2,042 · 2023: $2,651 · 2024: $2,738 · 2025: $4,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,275 · Consulting Fee: $2,158 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,275.47 |
| Consulting Fee | $2,158.38 |
| Education | $234.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $2,317.31 | 2022-2025 | Quzyttir |
| Astrazeneca Pharmaceuticals Lp | $1,964.11 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,492.74 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,338.87 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $1,181.65 | 2019-2025 | |
| Alk-Abello, INC | $1,011.81 | 2019-2023 | Odactra, Grastek |
| Csl Behring | $795.84 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $745.13 | 2020-2025 | Xembify |
| Blueprint Medicines Corporation | $540.84 | 2021-2025 | Ayvakit |
| Amgen INC. | $537.32 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $514.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $485.90 | 2020-2025 | Takhzyro, Eohilia |
| Pfizer INC. | $472.49 | 2019-2024 | |
| Pharming Healthcare, INC. | $408.44 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $389.52 | 2020-2025 | Xolair |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $310.19 | 2022-2025 | Adbry, Anzupgo |
| Teva Pharmaceuticals USA, INC. | $306.00 | 2020-2023 | Airduo Digihaler |
| Octapharma USA, INC. | $290.90 | 2019-2023 | Cutaquig |
| Organon LLC | $285.11 | 2025 | Vtama |
| Kaleo, INC. | $273.38 | 2019-2024 | Auvi-Q |
| Lilly USA, LLC | $161.14 | 2024-2025 | Ebglyss, Taltz |
| Optinose US, INC. | $153.85 | 2019-2025 | |
| Shire North American Group INC | $153.53 | 2019 | |
| Ionis Pharmaceuticals, INC. | $142.68 | 2025 | Dawnzera |
| Incyte Corporation | $129.80 | 2021-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.11 | 2019-2021 | |
| Phadia US INC. | $118.60 | 2021-2024 | Immunocap |
| Biocryst US Sales Co., LLC | $67.84 | 2021-2024 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Intersect Ent, INC. | $56.04 | 2019 | |
| Gc Biopharma USA, INC. | $55.34 | 2024-2025 | Alyglo, Alyglo |
| Azurity Pharmaceuticals, INC. | $49.12 | 2025 | Alvesco |
| Adma Biomanufacturing LLC | $38.40 | 2020-2024 | |
| Abbvie INC. | $23.57 | 2022 | |
| Kedrion Biopharma, INC. | $22.89 | 2025 | Kedrab, Albuked, Koate |
| Jubilant Hollisterstier LLC | $21.01 | 2025 | |
| Biocryst Pharmaceuticals, INC. | $19.95 | 2020 | |
| Merck Sharp & Dohme LLC | $18.88 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.27 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $15.99 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $15.10 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.